Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses
Selling, general and administrative	$ 233,109	$ 420,862	$ 689,111	$ 894,596
Research and development expense	105,837		461,969
Depreciation and amortization expense	13,377		40,531
Total operating expense	352,323	420,862	1,191,611	894,596
Loss from operations	(352,323)	(420,862)	(1,191,611)	(894,596)
Other income (expense):
Gain on issuance of license agreement				3,165,151
Loss on settlement of obligations		(1,467,271)	(40,000)	(1,169,691)
Loss from warrant modification and debt settlement		(594,288)		(1,605,913)
Impairment loss investment in common stock				(2,645,000)
Interest expense	(36,437)	(11,034)	(77,499)	(107,102)
Total other expense, net	(36,437)	(2,072,593)	(117,499)	(2,362,555)
Net loss	(388,760)	(2,493,455)	(1,309,110)	(3,257,151)
Net loss attributable to common stockholders	$ (388,760)	$ (2,493,455)	$ (1,309,110)	$ (3,257,151)
Basic loss income per share attributable to common stockholders	$ (0.00)	$ (0.04)	$ (0.02)	$ (0.16)
Diluted loss earnings per share attributable to common stockholders	$ (0.00)	$ (0.04)	$ (0.02)	$ (0.16)
Basic weighted average number of shares outstanding	83,239,115	60,089,305	83,461,806	20,643,181
Diluted weighted average number of shares outstanding	83,239,115	60,089,305	83,461,806	20,643,181